All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Thrasos Innovation Inc. kicked off a Phase I trial investigating the safety and tolerability of THR-184, an activator of specific receptors in the bone morphogenetic protein (BMP) receptor pathway. The peptides are designed to help protect and repair acutely injured kidneys. Although acute kidney injury (AKI) is a source of significant morbidity and mortality following surgery – and a major frustration for physicians – there is no approved drug therapy for the condition.